文献速递肾小球疾病

膜性肾病靶抗原诊断路径的优化

Optimization of a Target Antigen Diagnostic Pathway for Membranous Nephropathy.
PubMed 文献 · Kidney Int Rep · 2026-05-06

该双中心回顾性研究纳入816例有PLA2R染色的肾活检患者,发现PLA2R阳性率73.90%,在PLA2R阴性且资料完整的159例中EXT1/2(9.43%)和NELL1(7.55%)是最常见非PLA2R抗原,两种序贯策略最终累计诊断率均为83.33%,多数7抗原阴性患者(64.29%)为继发性膜性肾病。

要点

  • 中国PLA2R阴性且不典型患者中EXT1/2和NELL1为主要非PLA2R抗原。
  • 按本地患病率序贯检测(PLA2R→EXT1/2→NELL1)资源高效,同步检测节省时间。
  • 7抗原阴性者多数为继发性膜性肾病,以狼疮肾炎为主。

核心结论

  • 在中国PLA2R阴性且具不典型特征的患者中,EXT1/2和NELL1是主要非PLA2R抗原。
  • 按本地患病率序贯检测资源高效,同步检测节省时间。

研究设计与样本

  • 双中心回顾性研究,纳入816例有PLA2R染色的肾活检患者(2008-2023年)。
  • 对PLA2R阴性且具不典型特征且有组织者检测THSD7A、NELL1、EXT1/2、SEMA3B和PCDH7。

主要发现

  • PLA2R阳性率为73.90%。
  • 在PLA2R阴性且资料完整者(n=159)中,EXT1/2占9.43%,NELL1占7.55%,两者近乎完全互斥。
  • 两种序贯策略(Mayo顺序 vs 本队列推导顺序)最终累计诊断率均为83.33%。
  • 多数7抗原阴性患者(64.29%)为继发性膜性肾病,以狼疮肾炎为主。

关键数值与推荐

  • PLA2R阳性率73.90%。
  • PLA2R阴性且资料完整者(n=159)中EXT1/2为9.43%,NELL1为7.55%。
  • 两种序贯策略最终累计诊断率均为83.33%。
  • 7抗原阴性患者中64.29%为继发性膜性肾病。

临床怎么用

  • 对PLA2R阴性且具不典型特征的中国患者,可优先检测EXT1/2和NELL1。
  • 资源有限时按本地患病率序贯检测(PLA2R→EXT1/2→NELL1),需快速诊断时可同步检测。
  • 7抗原阴性者应评估继发性病因,尤其狼疮肾炎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The recent Mayo Clinic consensus proposed a target antigen-based diagnostic pathway for membranous nephropathy (MN), recommending testing for neural epidermal growth factor-like 1 (NELL1) following a negative phospholipase A2 receptor (PLA2R) result. This study aimed to optimize this pathway in a real-world Chinese cohort enriched for diagnostic complexity. METHODS: This dual-center retrospective study included 816 patients with PLA2R staining on renal biopsy (2008-2023). PLA2R-negative patients with atypical features and available tissue underwent comprehensive testing for thrombospondin type-1 domain-containing 7A (THSD7A), NELL1, exostosin1/2 (EXT1/2), semaphorin 3B (SEMA3B), and protocadherin 7 (PCDH7). Testing efficiency was simulated in a subcohort comprising all PLA2R-positive patients and PLA2R-negative patients with complete antigen data. RESULTS: PLA2R positivity was 73.90%. Among PLA2R-negative patients (n = 159 with complete data), EXT1/2 (9.43%), and NELL1 (7.55%) were the most prevalent non-PLA2R antigens, with near-complete mutual exclusivity. Two sequential strategies (Mayo order vs. our cohort-derived order) achieved identical final cumulative diagnostic yield (83.33%). Most 7-antigen-negative patients (64.29%) had secondary MN, predominantly lupus nephritis (LN). CONCLUSION: In Chinese PLA2R-negative patients with atypical features, EXT1/2 and NELL1 are the predominant antigens. Sequential testing by local prevalence (PLA2R → EXT1/2 → NELL1) is resource-efficient, whereas concurrent testing offers time savings. This practical framework aids diagnostic optimization, especially for patients with an autoimmune phenotype.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Li W, Huang C, Yue S, et al. Optimization of a Target Antigen Diagnostic Pathway for Membranous Nephropathy. Kidney Int Rep. 2026. PMID: 42305256. doi:10.1016/j.ekir.2026.106582

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。